AbbVie has reported positive results from the Phase II CELEST clinical trial of upadacitinib (ABT-494) for the treatment of patients with Crohn's disease.

Upadacitinib is an oral, selective inhibitor of JAK1, which is considered to be pivotal in the pathophysiology of the disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Results from the randomised, double-blind, placebo-controlled Phase II trial indicated that the number of patients experiencing endoscopic remission was more in the case of treatment with 24mg or 6mg of upadacitinib twice-daily when compared to placebo.

The trial assessed the safety and efficacy of various dosing regimens of upadacitinib over 16 weeks in adults with moderately to severely active Crohn's disease.

"For nearly two decades, AbbVie has pioneered research in immune-mediated diseases, and these findings demonstrate our commitment to meaningful scientific innovation with the potential to improve patient lives."

AbbVie research and development executive vice-president and chief scientific officer Michael Severino said: "Results from CELEST are encouraging and provide new information to the gastroenterology community on the potential for upadacitinib as an oral treatment option for patients with Crohn's disease.

"For nearly two decades, AbbVie has pioneered research in immune-mediated diseases, and these findings demonstrate our commitment to meaningful scientific innovation with the potential to improve patient lives."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The safety profile of upadacitinib was found to be consistent with the results obtained from its trials for the treatment of rheumatoid arthritis.

The overall adverse events (AEs) and infections in the Phase II trial were found to be numerically higher compared to placebo, but are not considered to be dose-related.

The ongoing trial will continue assessing patients up to 52 weeks.